The SQUEEZE project will help with the optimization of existing treatments for Rheumatoid Arthritis (RA) by exploring the latest developments in the field of biomarkers, focusing on the effect and safety of medicines and analysing the best implementation science to enhance the therapeutic relationship.

Welcome to the SQUEEZE Project

Rheumatoid arthritis (RA) is a chronic immune-mediated condition with enormous socioeconomic and individual impact. Despite the availability of various treatment options, every patient seems to respond differently. ​Furthermore, the unsuccessful choice of the most suitable medication for a particular patient can lead to a scenario in which the patient consumes a drug that doesn’t align with their body’s response, ultimately aggravating the patient’s condition. We, at SQUEEZE, in synergy with other EU-wide activities, work to validate clinical, laboratory, molecular, digital, and behavioural biomarkers to help tailor the best treatment to the individual patient.Our aim is to improve the efficacy, safety, and satisfaction with existing therapies (by squeezing the most out of them!).



€ 8 602 316,25

5 years


We are a team of leading academic centres with a first-class record in translational and clinical research, together with patients and small and medium sized enterprises (SMEs).

SQUEEZE project

We aim to have a real impact on life of people with rheumatoid arthritis


SQUEEZE featured as a SuccessStory of the FFG

December 7th, 2023|

The Austrian Research Promotion Agency (FFG), the national funding agency for industrial research and development in Austria, has chosen our project SQUEEZE to be featured in one of their articles serie #SuccessStory, with the [...]

SQUEEZE featured in Trend

September 21st, 2023|

Our SQUEEZE project and coordinator Daniel Aletaha have been showcased in the Austrian magazine Trend! 👏 The article spotlights EU-funded initiatives in Austria and highlights the European Union's substantial commitment to research via the [...]